Results 241 to 250 of about 38,667 (276)

Defense heterosis as a novel plant protection strategy: From theory to breeding practice

New Plant Protection, EarlyView.
Defense heterosis, the enhanced disease resistance of hybrids compared to their parents, has evolved from early observations of hybrid vigor to a novel research concept. Advances are now clarifying its diverse genetic and molecular mechanisms across various plant–pathogen interactions.
Kaiqi Xu, Xue Li, Fangfang Li
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

HIV infection dynamics and viral rebound: Modeling results from humanized mice

Journal of Theoretical Biology, 2023
Despite years of combined antiretroviral therapy (cART), HIV persists in infected individuals. The virus also rebounds after the cessation of cART. The sources contributing to viral persistence and rebound are not fully understood. When viral rebound occurs, what affects the time to rebound and how to delay the rebound remain unclear. In this paper, we
Guo, Ting, Deng, Qi, Qiu, Zhipeng, Rong, Libin   +3 more
openaire   +3 more sources

Control of viral rebound through therapeutic immunization with DermaVir

AIDS, 2005
To reconstitute immune responses capable of eliminating infected cells and suppressing viral load during chronic retroviral infection.: A topical, DNA-based therapeutic immunization (DermaVir) was designed to express most of the regulatory and structural viral genes in dendritic cells.DermaVir alone and in combination with antiretroviral drugs was ...
Julianna, Lisziewicz, Jeffrey, Trocio, Jianqing, Xu, Lucia, Whitman, Amy, Ryder, Nyasha, Bakare, Mark G, Lewis, Wendeline, Wagner, Angela, Pistorio, Suresh, Arya, Franco, Lori   +10 more
openaire   +2 more sources

Proviral HIV-DNA predicts viral rebound and viral setpoint after structured treatment interruptions

AIDS, 2004
In HIV-1-infected patients with long-term undetectable viraemia on highly active antiretroviral treatment (HAART), we found that pre-HAART plasma viraemia and the baseline proviral DNA level were significantly associated with the viraemia setpoint during scheduled treatment interruptions.
Yerly Ferrillo, Sabine, Gunthard, Huldrych, Fagard, Catherine, Joos, Beda, Perneger, T. V., Hirschel, Bernard, Perrin, Luc   +6 more
openaire   +3 more sources

Modelling HIV viral rebound using non‐linear mixed effects models

Statistics in Medicine, 2002
Abstract Individuals infected with the human immunodeficiency virus type 1 (HIV‐1) who initiate antiretroviral therapy typically experience a marked decline in concentrations of HIV‐1 RNA in plasma. Often, however, viral rebound occurs within the first year of treatment and this rebound may be associated with resistance to antiretroviral therapy.
Anthony P, Fitzgerald, Victor G, DeGruttola, Florin, Vaida   +2 more
openaire   +2 more sources

Resistance Profiles in Patients with Viral Rebound on Potent Antiretroviral Therapy

The Journal of Infectious Diseases, 2000
The prevalence of phenotypic drug resistance was assessed in 60 patients with a viral rebound after they received a protease inhibitor (PI)- or nonnucleoside reverse transcriptase inhibitor (NNRTI)-containing regimen (baseline). Resistance testing was done within 36 weeks of viral rebound; no resistance testing was available at baseline.
A, Cozzi Lepri, C A, Sabin, S, Staszewski, K, Hertogs, A, Müller, H, Rabenau, A N, Phillips, V, Miller   +7 more
openaire   +2 more sources

Poor retention in care one-year after viral suppression: a significant predictor of viral rebound

AIDS Care, 2014
Optimal retention in care should be continuously monitored even after suppression to prevent the risk of viral rebound. The purpose of this study is to assess the association between retention in care and viral rebound 12 months after viral suppression.
openaire   +3 more sources

Interferon May Prevent HIV Viral Rebound After HAART Interruption in HIV Patients

Journal of Interferon & Cytokine Research, 2008
In the pre-highly active antiretroviral therapy (HAART) era, clinical trials showed that interferon (IFN) treatment was able to delay AIDS progression and prolong survival. Along with HAART, ancillary use of IFN during primary infection and before HAART therapy initiation has been effective.
Ferdinando, Dianzani, Gabriella, Rozera, Isabella, Abbate, Gianpiero, D'Offizi, Amina, Abdeddaim, Chrysoula, Vlassi, Giorgio, Antonucci, Pasquale, Narciso, Federico, Martini, Maria R, Capobianchi   +9 more
openaire   +2 more sources

Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?

AIDS, 2008
We investigated whether previous treatment interruptions are associated with a raised risk of viral rebound in individuals who have attained virological suppression.All patients achieving an undetectable viral load while on therapy were followed until viral rebound or the time of the last viral load.
Loveleen K, Bansi, Andrew A, Benzie, Andrew N, Phillips, Simon, Portsmouth, Teresa, Hill, Clifford, Leen, Achim, Schwenk, Margaret, Johnson, Jane, Anderson, Richard, Gilson, Philippa, Easterbrook, Brian, Gazzard, Martin, Fisher, Chloe, Orkin, Kholoud, Porter, Deenan, Pillay, Graham P, Taylor, John C, Walsh, Caroline A, Sabin   +18 more
openaire   +2 more sources

Factors associated with viral rebound among highly treatment‐experienced HIV‐positive patients who have achieved viral suppression

HIV Medicine, 2008
ObjectiveMore and more highly treatment‐experienced patients are achieving viral suppression. However, the durability of suppression remains unclear.MethodsPatients from Royal Free Hospital (London, UK) and JW Goethe University Hospital (Frankfurt, Germany) who had failed ≥1 antiretroviral (ARV) regimen in all three main drug classes and ≥3 previous ...
C J, Smith, A N, Phillips, B, Dauer, M A, Johnson, F C, Lampe, M S, Youle, M, Tyrer, S, Staszewski   +7 more
openaire   +2 more sources